Innovent Biologics Inc., a biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, has signed a non-exclusive, target-specific license agreement  with Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index.   Under the terms of the agreement, Synaffix...